The deficit widened mainly on account of poor revenue realisation. The lockdown imposed to curb spreading of coronavirus infections had significantly impacted business activities and in turn contributed to sluggish revenue realisation

In the reporting week, the increase in the forex kitty was on account of a rise in foreign currency assets (FCAs), a major component of the overall reserves

Industry experts had warned that a 10% cap would hit revenue and operations of the likes of Uber, which have faced increased regulatory scrutiny in several countries

CAIT National President BC Bhartia and Secretary General Praveen Khandelwal said that penalising Amazon India with such a small amount for violating Indian law is nothing but a mockery of the country's judicial and administrative system

Serum Institute of India is expected to produce 100 crore doses of the Oxford-AstraZeneca vaccine candidate. These doses will be given to middle and low-income countries, including India. SII has now agreed to provide 3 crore doses to Bangladesh

The mission envisages Covid-19 vaccine development with end-to-end focus from preclinical through clinical development and manufacturing and regulatory facilitation, the DBT said

Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021

India has urged the World Trade Organisation to waive off intellectual property rights on vaccines, treatments or technologies that could prove helpful in global attempts to combat coronavirus pandemic

A blow-by-blow account of how Indian vaccines are being readied

The extension, announced by the UK Home Office last Friday, will cover healthcare professionals working in the National Health Service (NHS) and the independent health and care sector

Dozens of countries have signed up to the global vaccine plan known as COVAX, which was set up by the WHO and the GAVI vaccine group to provide vaccine doses for countries that could not otherwise afford them

Serum Institute has tied up with British-Swedish pharmaceutical firm AstraZeneca and the University of Oxford to mass-produce the Covishield vaccine to fight back COVID-19 virus

Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public

Addressing the virtual G20 Summit hosted by Saudi Arabia's King Salman, Xi said China will always be a builder of global peace, a contributor to global development and a defender of international order

The twin crises of the pandemic and an uneven, uncertain global recovery dominated the first day of a two-day summit under the chairmanship of Saudi Arabia, which hands off the rotating presidency of the G20 to Italy next month

Adar Poonawalla said if things go according to the plan, the coronavirus vaccine will be available for vulnerable populations by January or February. And, in March or April, the vaccine will enter the market for the general public

The GAVI alliance said on Friday that the funds for an advance market commitment (AMC) will allow the COVAX facility to buy an initial one billion vaccine doses for 92 eligible countries

Serum Institute has tied up with five developers that have made 40 million doses of the coronavirus vaccine in the past two months. They are aiming to start manufacturing of Novavax's candidate soon

Nirmala Sitharaman press conference: The minister said that the Rs 900 crore funding to the Department of Biotechnology will be for research purposes only

COVID-19 vaccine update: Based on the success of the trials and regulatory approvals, we can expect vaccine to be available in India by January 2021, only if its proven immunogenic and efficacious, says SII CEO Adar Poonawalla